

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

UCB, INC., UCB BIOPHARMA SPRL,)
RESEARCH CORPORATION)
TECHNOLOGIES, INC. and HARRIS FRC)
CORPORATION,)

Plaintiffs,)

v.)

ACCORD HEALTHCARE, INC., et al.,)


Defendants.)

C.A. No. 13-1206-LPS
CONSOLIDATED

ORDER

At Wilmington this 14th day of May, 2015:

For the reasons set forth in the Memorandum Opinion issued this date, IT IS HEREBY ORDERED that the term “therapeutic composition,” which appears in claim 10 of U.S. Reissued Pat. No. RE 38,551 (“the ’551 Patent”), is construed to mean “a composition suitable for use as a treatment regimen over an extended period of time (chronic administration).”



HON. LEONARD P. STARK
UNITED STATES DISTRICT JUDGE